Skip to main content
 

X

 
News

BeiGene News

See all News

  • September 19, 2022
    BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma

    BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma

  • September 19, 2022
    NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment

    NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment

  • September 10, 2022
    BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer

    BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer

  • September 7, 2022
    BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

    BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

  • August 23, 2022
    BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China

    BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China

  • August 15, 2022
    BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care

    BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care

  • BeiGene Facts
  • 2010Founded
  • NASDAQ: BGNE  
    HKEX: 06160
    Listings
  • 8Internally Developed
    Clinical Candidates
  • 8Marketed
    Products
    in China
  • 1Approved
    Product
    in the U.S.
  • 8,000+Global Team

Partnering

Partnerships that Extend Around the Globe

BeiGene is the partner of choice in China for development and commercialization. Read more about our current partnerships and opportunities to build business relationships.

Partners

ZymeworksLeapSeagen_LogoAmbrx LogoMirati LogoMEIAmgen logoEUSA LogoAssembly Bio LogohutchmedBio-Thera LogoSinglomics LogostandtxBITT LogoNovartisShoreline

Our Patients

Our Commitment to Patients

At BeiGene we are focused not only on the underserved global cancer patient population, but also on individual people fighting their illnesses.

Patients

Careers
 

Careers

Join Our
Team

We’re looking for highly motivated colleagues who can collaborate with us as we build a company that will have a lasting impact on the global fight against cancer.

Careers